Minocycline to Treat Amyotrophic Lateral Sclerosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00047723 |
|
Recruitment Status :
Completed
First Posted : October 17, 2002
Last Update Posted : December 21, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Amyotrophic Lateral Sclerosis | Drug: minocycline | Phase 3 |
ALS is a progressive neurodegenerative disorder without cure or known treatment that significantly improves function. Loss of motor neurons in the brain and spinal cord of ALS patients causes the progressive symptoms. Laboratory studies have linked inducible nitric oxide synthase (iNOS) and caspase enzyme activation to motor nerve cell death in ALS. Minocycline-a medication currently approved by the FDA for treatment of bacterial infections-is a tetracycline antibiotic with high central nervous system penetration when taken orally. The drug inhibits the activity of iNOS and caspase enzymes.
Minocycline has been tested and shown to protect nerve cells in many scientific experiments. It reduces cell death and prolongs survival in animal models of ALS, stroke, trauma, Huntington's disease, and Parkinson's disease. It has been shown to be beneficial in many different animal experiments of ALS, conducted in Europe, Canada and the United States.
Minocycline has been tested in 2 preliminary human trials and has been shown to be safe in patients with ALS. It has been well tolerated in conjunction with riluzole (Rilutek), the only currently FDA-approved medication for ALS.
This trial is the final important step in determining whether minocycline improves the course of ALS. The principle objective of this clinical trial is to determine whether minocycline slows disease progression and helps maintain function in patients with ALS. This multi-center placebo-controlled study will select patients early in the course of ALS, when a neuroprotective therapy may be most beneficial. The study will measure change in function (as detected by ALSFRS-R scores), strength, pulmonary function, survival, and quality of life. Participants will undergo monthly outpatient evaluations and analysis of laboratory and adverse events. This is a 13-month study.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 400 participants |
| Allocation: | Randomized |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Study Start Date : | January 2003 |
| Actual Study Completion Date : | January 2007 |
- Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.
- Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
To be eligible for enrollment in this study, subjects must meet the following eligibility criteria within fourteen days prior to randomization:
Inclusion criteria:
- A clinical diagnosis of laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria.
- FVC greater or equal to 75% of predicted.
- Onset of weakness within 3 years prior to enrollment.
- If patients are receiving riluzole they must be on a stable dose for at least the past thirty days.
- Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test (adequate birth control includes use of intra-uterine device or oral contraceptives plus a barrier method, e.g. condom, diaphragm).
- Willing and able to give signed informed consent that has been approved by your Institutional Review Board (IRB).
Exclusion criteria:
- Requirement for tracheotomy ventilation (or non-invasive ventilation > 23 hours/day).
- Diagnosis of other neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, etc).
- FVC < 75% of predicted.
- A clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days.
- History of renal disease (screening creatinine greater than 1.5).
- History of liver disease (screening alanine aminotransferase greater than 3 times the upper limit of normal).
- History of hematologic disease (screening white blood cell count less than 3,800/mm3).
- History of system lupus erythematosis (or screening ANA of 1:160 or greater).
- Treatment with any medications that may cause lupus-like symptoms within 4 weeks of baseline visit (e.g. procainamide, hydralazine).
- History of vestibular disease (excluding benign position vertigo).
- Pregnancy or lactation.
- Allergy to tetracycline antibiotics.
- Use of minocycline within thirty days of enrollment (baseline visit).
- Use of anti-epileptic medications other than gabapentin.
- Limited mental capacity rendering the subject unable to provide written informed consent or comply with evaluation procedures.
- History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols.
- Use of any investigational drug within the past 30 days (Creatine, Vioxx, Celebrex, Topiramate).
- Women with the potential to become pregnant who are not practicing effective birth control.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00047723
Show 30 study locations
| Principal Investigator: | Paul H. Gordon, M.D., | Associate Medical Director, Eleanor and Lou Gehrig MDA/ALS Center, Columbia University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00047723 |
| Other Study ID Numbers: |
R01NS045294 ( U.S. NIH Grant/Contract ) |
| First Posted: | October 17, 2002 Key Record Dates |
| Last Update Posted: | December 21, 2007 |
| Last Verified: | December 2007 |
|
ALS amyotrophic lateral sclerosis minocycline |
|
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases Spinal Cord Diseases |
Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Minocycline Anti-Bacterial Agents Anti-Infective Agents |